Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional Results available

First in Patient Study for PF-06840003 in Malignant Gliomas

ClinicalTrials.gov ID: NCT02764151

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02764151. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06840003 IN PATIENTS WITH MALIGNANT GLIOMAS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.

Study identification

NCT ID
NCT02764151
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Pfizer
Industry
Enrollment
17 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 9, 2016 (Actual)
Primary completion
Dec 26, 2018 (Actual)
Completion
Dec 26, 2018 (Actual)
Last update posted
Jan 27, 2020

2016 – 2018

United States locations

U.S. sites
14
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
Ronald Reagan UCLA Medical Center Los Angeles California 90095-6894 —
UCLA Clinical & Translational Research Center Los Angeles California 90095 —
UCLA Oncology Center Los Angeles California 90095 —
UCLA School of Medicine Los Angeles California 90095 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Brigham & Women's Hospital Boston Massachusetts 02115 —
Dana-Farber Cancer Institute Boston Massachusetts 02215 —
University of New Mexico Comprehensive Cancer Center Albuquerque New Mexico 87102 —
Columbia University Medical Center New York New York 10019 —
Columbia University Medical Center New York New York 10032 —
CUMC Research Pharmacy New York New York 10032 —
Columbia Doctors Tarrytown Tarrytown New York 10591 —
Duke Cancer Center Durham North Carolina 27710 —
Duke University Medical Center, Duke Cancer Center Durham North Carolina 27710 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02764151, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 27, 2020 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.